Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?

Critical Reviews in Oncology/Hematology

Volumn 72, Issue 1, 2009, Pages 56-64

  Freedman, Orit C ^a,b   Amir, Eitan ^a,b   Clemons, Mark J ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bisphosphonate; Cancer induced bone loss

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CAPECITABINE; CLODRONIC ACID; COLECALCIFEROL; CYCLOPHOSPHAMIDE; ETIDRONIC ACID; FLUOROURACIL; GOSERELIN; IBANDRONIC ACID; LETROZOLE; METHOTREXATE; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE; ZOLEDRONIC ACID;

ACUTE KIDNEY TUBULE NECROSIS; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; EYE DISEASE; FEVER; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLOMERULOPATHY; HUMAN; JAW OSTEONECROSIS; KIDNEY TUBULE DISORDER; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OPTIMAL DRUG DOSE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BONE DISEASES; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; FEMALE; HUMANS;

EID: 69249202481     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.03.001     Document Type: Review

References (82)

1. Ferlay J., Bray F., Pisani P., et al. Globocan 2002: cancer incidence, mortality and prevalence worldwide, version 2.0: IARC CancerBase no. 5 (2004), IARC Press, Lyon
2. Coleman R.E. Skeletal complications of malignancy. Cancer 80 (1997) 1588-1594
3. Theriault R.L., and Hortobagyi G.N. Bone metastasis in breast cancer. Anticancer Drugs 3 (1992) 445-462
4. Solomayer E.F., Diel I.J., Meyberg G.C., et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59 (2000) 271-278
5. Saad F., Lipton A., Cook R., et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110 8 (2007) 1860-1867
6. Friedlaender G.E., Tross R.B., Doganis A.C., et al. Effects of chemotherapeutic agents on bone I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Surg Am 66 (1984) 602-607
7. Delmas P.D., and Fontana A. Bone loss induced by cancer treatment and its management. Eur J Cancer 34 (1998) 260-262
8. Pfeilschifter J., and Diel I.J. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18 (2000) 1570-1593
9. Russell R.G.G., and Rogers M.J. Bisphosphonates: from the laboratory to the clinic, and back again. Bone 25 (1999) 97-106
10. Amin D., Cornell S.A., Gustafson S.K., et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33 (1992) 1657-1663
11. Rogers M.J., Gordon S., Benford H.L., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (2000) 2961-2978
12. Hortobagyi G.N., Theriault R.L., Lipton A., et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16 (1998) 2038-2044
13. Theriault R.L., Lipton A., Hortobagyi G.N., et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17 (1999) 846-854
14. Lipton A., Theriault R.L., Hortobagyi G.N., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 88 (2000) 1082-1090
15. Hultborn R., Gundersen S., Ryden S., et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 19 (1999) 3383-3392
16. Kohno N., Aogi K., Minami H., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23 (2005) 3314-3321
17. Body J.J., Diel I.J., Lichinitzer M., et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo-controlled phase III studies. Br J Cancer 90 (2004) 1133-1137
18. Body J.J., Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14 (2003) 1399-1405
19. Paterson A.H.G., Powles T.J., Kanis J.A., et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11 (1993) 59-65
20. Kristensen B., Ejlertsen B., Grunvold M., et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246 (1999) 67-74
21. Tubiana-Hulin M., Beuzeboc P., Mauriac L., et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 88 (2001) 701-707
22. van der Pluijm G., Vloedgraven H., van Beek E., et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98 (1996) 698-705
23. Neudert M., Fischer C., Krempien B., et al. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. Int J Cancer 107 (2003) 468-477
24. Wood J., Bonjean K., Ruetz S., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302 (2002) 1055-1061
25. Mundy G. Preclinical models of bone metastases. Semin Oncol 28 (2001) 2-8
26. Diel I.J. Bisphosphonates in the prevention of bone metastases: current evidence. Semin Oncol 28 (2001) 75-80
27. Padalecki S.S., and Guise T.A. Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Res 4 (2002) 35-41
28. Neville-Webbe H.L., Holen I., and Coleman R.F. The anti-tumor activity of bisphosphonates. Cancer Treat Rev 28 (2002) 305-319
29. Diel I.J., Solomayer E.F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339 (1998) 357-363
30. Jaschke A., Bastert G., Solomayer E.F., et al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow a longtime follow-up. Proc Am Soc Clin Oncol 22 (2004) [abstract 529]
31. Diel I.J., Jaschke A., Solomayer E.F., et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 19 (2008) 2007-2011
32. Powles T., Paterson S., Kanis J.A., et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20 (2002) 3219-3224
33. Powles T., Paterson A., McCloskey E., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 8 (2006) 1-7
34. Saarto T., Blomqvist C., Virkkunen P., and Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19 (2001) 10-17
35. Saarto T., Vehmanen L., Virkkunen P., and Blomqvist C. Ten-year follow up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43 7 (2004) 650-656
36. Powles T., Paterson A., McCloskey E., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 8 (2006) R13
37. Powles T.J., McCloskey E., Paterson A.H.G., et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90 (1998) 704-708
38. Paterson A.G. The role of bisphosphonates in early breast cancer. Oncologist 11 Suppl. 1 (2006) 13-19
39. Ha T.C., and Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer 96 (2007) 1796-1801
40. Ross J.R., Saunders Y., Edmonds P.M., et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Tech Assess 8 4 (2004)
41. Pavlakis N., Schmidt R.L., and Stockler M.R. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3 (2005) CD003474
42. Kokufu I., Kohno N., Takao S., et al. Adjuvant pamidronate (PMT) therapy for the prevention of bone metastasis in breast cancer (BC) patients (pts) with four or more positive nodes. Proc Am Soc Clin Oncol 23 (2004) 8 (abs 530)
43. Kristensen B., Ejlertsen B., Mouridson H.T., et al. Bisphosphonate treatment in primary breast cancer: results from a randomized comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 47 (2008) 740-746
44. Avilés A., Nambo M.J., Neri N., Castaéeda C., Cleto S., and Huerta-Guzmán J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 24 (2007) 227-230
45. Daubiné F., Le Gall C., Gasser J., Green J., and Clézardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99 (2007) 322-330
46. Santini D., Vincenzi B., Galluzzo S., et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13 (2007) 4482-4486
47. Rack B.K., Janni W., Schindlbeck C., et al. Effect of zoledronate on persisting isolated tumor cells (ITC) in the bone marrow (BM) of patients without recurrence of early breast cancer. Proc Am Soc Clin Oncol (2004) 23 [abstract 9515]
48. Lin A., Park J., Melisko M., et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Breast Cancer Res Treat 106 Suppl. 1 (2007) 510
49. Mystakidou K., Katsouda E., Parpa E., Kelekis A., Galanos A., and Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 22 (2005) 195-201
50. Gnant M., Mlineritsch B., Schippinger W., et al. On behalf of the ABCSG 12 trial investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360 (2009) 679-691
51. Brufsky A., Harker W.G., Beck J.T., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25 (2007) 829-836
52. Bundred N.J., Campbell I.D., Davidson N., et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 112 (2008) 1001-1010
53. De Boer R., Eidtmann H., Lluch A., et al. The ZO-FAST trial: zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24 month BMD results. Breast Cancer Res Treat 106 Suppl. 1 (2007) 501
54. Brufsky A., Lund K., Cobb P., et al. Twenty-four month follow-up of the effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Breast Cancer Res Treat 100 Suppl. 1 (2006) 5060
55. Brufsky A., Bosserman L., Caradonna R., et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: The Z-FAST study 36-month follow-up. Breast Cancer Res Treat 106 Suppl. 1 (2007) 27
56. Brufsky A., Bundred N., Coleman R., et al. Z-FAST and ZO-FAST Study Groups Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13 (2008) 503-514
57. Eidtmann H., Bundred N.J., DeBoer R., et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 month follow up o ZO-FAST. Cancer Res 69 Suppl. 2 (2009) 44
58. Winter M.C., Thorpe H.C., Burkinshaw R., et al. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response-exploratory evidence for direct anti-tumor activity in breast cancer. Cancer Res 69 Suppl. 2 (2009) 5101
59. Ioannidis J.P., Cappelleri J.C., and Lau J. Issues in comparisons between meta-analyses and large trials. JAMA 279 14 (1998) 1089-1093
60. Bergner R., Diel I.J., Henrich D., et al. Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 29 (2006) 534-540
61. van der Klift M., de Laet C.E., Coebergh J.W., et al. Bone mineral density and the risk of breast cancer: The Rotterdam Study. Bone 32 (2003) 211-216
62. Kanis J.A., McCloskey E.V., Powles Tet al. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79 (1999) 1179-1181
63. Eastell R., Hannon R.A., Cuzick J., et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen alone or in combination (ATAC) trial (18233230). J Bone Miner Res 21 (2006) 1215-1223
64. Kanis J.A., and McCloskey E.V. Clodronate. Cancer 80 (1997) 1691-1695
65. Saarto T., Blomqvist C., Valimaki M., et al. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 75 (1997) 602-605
66. Delmas P.D., Balena R., Confravreux E., et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15 (1997) 955-962
67. Gnant M.F., Mlineritsch B., Luschin-Ebengreuth G., et al. Zoledronic acid effectively prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25 7 (2007) 820-828
68. Aapro M., Abrahamsson P.A., Body J.J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19 (2008) 420-432
69. Hadji P., Body J.J., Aapro M.S., et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19 (2008) 1407-1416
70. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 (2001) 948-955
71. Greenspan S.L., Nelson J.B., Trump D.L., and Resnick N.M. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146 (2007) 416-424
72. Lester J.E., Gutcher S.A., Ellis S.P., et al. The ARIBON study: reversal of anastrozole (Arimidex) induced bone loss with oral monthly ibandronate (Bondronate) treatment during adjuvant therapy for breast cancer. Cancer Treat Rev 32 (2006) [abstract 121]
73. Mian M., Beghe F., Caprio A., et al. Tolerability and safety of clodronate therapy in bone diseases. Int J Clin Pharmacol Res 11 (1991) 107-114
74. Robertson A.G., Reed N.S., and Ralston S.H. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 13 (1995) 2427-2430
75. Clemons M., Dranitsaris G., Ooi W.S., Yogendran G., and Cole D.E.C. Oral ibandronate provides significant palliative benefit in metastatic breast cancer patients who have experienced bony progression or a skeletal related event (SRE) despite first-line bisphosphonate therapy. Breast Cancer Res Treat 100 Suppl. 1 (2006) 3147
76. Mangiapane S., Hoer A., Gothe H., et al. Higher persistency with i.v. bisphosphonates in patients with bone metastasis. J Clin Oncol 24 (2006) 698S
77. Chang J.T., Green L., and Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 349 (2003) 1676-1679
78. Johnson K.B., Gable P., Kaime E.M., et al. Significant deterioration in renal function with the new bisphosphonate, zoledronic acid. Proc Am Soc Clin Oncol 22 (2003) 46
79. Perazella M.A., and Markowitz G.S. Bisphosphonate nephrotoxicity. Kidney Int 74 (2008) 1385-1393
80. Kyle R.A., Yee G.C., Somerfield M.R., et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in the treatment of multiple myeloma. J Clin Oncol 25 (2007) 2464-2472
81. Khosla S., Burr D., Canley J., et al. Bisphosphonate associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 (2007) 1479-1491
82. Diel I.J., Fogelman I., Al-Nawas B., et al. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?. Crit Rev Oncol Hematol 64 (2007) 198-207